Grant-Huerta Yanina 4
4 · Atara Biotherapeutics, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
Grant-Huerta Yanina
Chief Accounting Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-02$5.08/sh−24$122→ 33,830 total - Sale
Common Stock
[F1][F2]2026-03-02$5.08/sh−1,603$8,145→ 32,227 total - Sale
Common Stock
[F1][F2]2026-03-02$5.08/sh−377$1,916→ 31,850 total - Sale
Common Stock
[F1][F2]2026-03-02$5.08/sh−100$508→ 31,750 total
Footnotes (3)
- [F1]Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
- [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
- [F3]This amount includes 400 shares purchased under the Issuer's Employee Stock Purchase Plan on November 28, 2025.
Signature
/s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta|2026-03-04